FY2025 EPS Estimates for GENFIT Lifted by Leerink Partnrs

Key Points

• Leerink Partners raised their FY2025 earnings estimate for GENFIT to ($0.27) per share, significantly up from the previous estimate of ($0.89).
• HC Wainwright lowered their price target for GENFIT from $9.00 to $7.00 while maintaining a "buy" rating, indicating mixed sentiments among analysts.
• An institutional investor recently acquired approximately 22,238 shares of GENFIT stock, reflecting growing interest among institutional stakeholders.

GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Free Report) - Research analysts at Leerink Partnrs upped their FY2025 earnings estimates for GENFIT in a note issued to investors on Monday, September 22nd. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($0.27) per share for the year, up from their prior estimate of ($0.89). The consensus estimate for GENFIT's current full-year earnings is $0.95 per share. Leerink Partnrs also issued estimates for GENFIT's FY2026 earnings at $0.11 EPS, FY2027 earnings at ($0.13) EPS, FY2028 earnings at ($0.71) EPS and FY2029 earnings at ($0.32) EPS.

Separately, HC Wainwright dropped their price target on shares of GENFIT from $9.00 to $7.00 and set a "buy" rating for the company in a research note on Wednesday. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, GENFIT has a consensus rating of "Buy" and an average price target of $7.00.

GENFIT Price Performance

GNFT opened at $3.63 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.74 and a quick ratio of 1.23. The firm has a 50 day simple moving average of $4.00 and a 200 day simple moving average of $3.90. GENFIT has a fifty-two week low of $2.55 and a fifty-two week high of $6.42.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in GENFIT stock. OLD Mission Capital LLC purchased a new stake in GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 22,238 shares of the company's stock, valued at approximately $76,000. Institutional investors and hedge funds own 2.24% of the company's stock.

GENFIT Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.